Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NCT05865496Phase 2Active, not recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SSGJ-611 in chronic rhinosinusitis with nasal polyps (CRSwNP) (3 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Change From Baseline in Bilateral Nasal Polyp Score at 16 weeks and Change From Baseline in Nasal Congestion Symptom Severity Score at 16 weeks. Started Jun 2023; status: active, not recruiting.
02
Drugs
SSGJ-611
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT05865496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05865496.